Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
Ticagrelor
AstraZeneca AB
B01AC24
ticagrelor
Antithrombotic agents
Peripheral Vascular Diseases; Acute Coronary Syndrome
Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
Revision: 2
Withdrawn
2010-12-03
28 B. PACKAGE LEAFLET Medicinal product no longer authorised 29 PACKAGE LEAFLET: INFORMATION FOR THE USER POSSIA 90 MG FILM-COATED TABLETS ticagrelor READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET 1. What Possia is and what it is used for 2. What you need to know before you take Possia 3. How to take Possia 4. Possible side effects 5. How to store Possia 6. Contents of the pack and other information 1. WHAT POSSIA IS AND WHAT IT IS USED FOR WHAT POSSIA IS Possia contains the active substance called ticagrelor. This belongs to a group of medicines called anti-platelet medicines. HOW POSSIA WORKS Possia affects cells called ‘platelets’ (also called thrombocytes). These very small blood cells help stop bleeding by clumping together to plug tiny holes in blood vessels that are cut or damaged. However, platelets can also form clots inside diseased blood vessels in the heart and brain. This can be very dangerous because: the clot can cut off the blood supply completely - this can cause a heart attack (myocardial infarction) or stroke, or the clot can partly block the blood vessels to the heart - this reduces the blood flow to the heart and can cause chest pain which comes and goes (called ‘unstable angina’). Possia helps stop the clumping of platelets. This reduces the chance of a blood clot forming that can reduce blood flow. WHAT POSSIA IS USED FOR Possia is to be used in adults only. You have been given Possia because you have had: a heart attack, or unstable angina (angina or chest pain that is Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Possia 90 mg film coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 90 mg ticagrelor. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Round, biconvex, yellow tablets marked with ‘90’ above ‘T’ on one side and plain on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG). For further information, please refer to section 5.1. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ _ Posology Possia treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily. Patients taking Possia should also take ASA daily, unless specifically contraindicated. Following an initial dose of ASA, Possia should be used with a maintenance dose of ASA of 75-150 mg (see section 5.1). Treatment is recommended for up to 12 months unless discontinuation of Possia is clinically indicated (see section 5.1). Experience beyond 12 months is limited. In patients with Acute Coronary Syndromes (ACS), premature discontinuation with any antiplatelet therapy, including Possia, could result in an increased risk of cardiovascular death, or myocardial infarction due to the patient’s underlying disease. Therefore, premature discontinuation of treatment should be avoided. Lapses in therapy should also be avoided. A patient who misses a dose of Possia should take only one 90 mg tablet (their next dose) at its scheduled time. Patients treated with clo Przeczytaj cały dokument